Although negative p16INK4a immunostaining ruled out CIN3 or carcinoma in 86.67% of patients with CIN2 biopsies in our study, positive p16INK4a staining did not guarantee that lesions were ≥ CIN3. Here, CDKN2A is linked to carcinoma.